|
Consensus recommendations |
Grade |
|
Assessment of comorbid conditions and liver disease cofactors, including HBV and HIV infection, should occur before commencing DAA therapy, and these conditions should be addressed before or concurrent with DAA therapy. |
A1 |
|
Documentation of HCV genotype may be considered before prescribing HCV therapy.. |
A1 |
|
Past HCV treatment experience should be documented, including regimen and response. |
A1 |
|
Detecting cirrhosis is essential to identify people requiring long-term management of chronic liver disease, and also determines treatment duration for some DAA regimens. |
A1 |
|
A non-invasive assessment of liver fibrosis is suitable for most people. |
A1 |
|
People with cirrhosis should be screened for complications including:
|
A1 |
|
All people with cirrhosis should be referred to, and managed in consultation with, a specialist familiar with the management of this condition. |
A1 |
|
Vaccination against HAV and HBV is recommended for all susceptible individuals with HCV infection. |
A1 |
|
All concomitant medications must be assessed for potential drug–drug interactions. |
A1 |